JAK1 and rheumatoid arthritis: A case report of baricitinib, a selective JAK1 and JAK2 inhibitor, use in a patient with ocular and systemic features of seronegative RA showed resolution of anterior chamber cell, corneal infiltrates, vitreous opacity, and serous retinal detachment at 3 month follow-up [17, 20].